Monash IVF Revises FY26 NPAT Guidance to $17-18 Million
Monash IVF lowers its FY26 underlying NPAT guidance to $17-18 million, citing a 4.7% drop in Australian stimulated IVF cycles. Despite this, the company has expanded its national market share to 20.1% and seen international volume growth.
- FY26 underlying NPAT guidance revised down to $17-18 million
- Australian ART stimulated cycle volumes decline 4.7% in H2
- Monash IVF increases national market share by 1.0% to 20.1%
- International operations showing strong second half volume growth
- Operational cost efficiencies to benefit FY27 earnings
Earnings Downgrade Reflects Weaker Australian IVF Market
Monash IVF Group (ASX:MVF) has adjusted its FY26 underlying net profit after tax (NPAT) forecast down to a range of $17 million to $18 million. The revision is primarily driven by softer-than-expected activity in the Australian assisted reproductive technology (ART) market during the second half of the financial year. Stimulated cycle volumes across Australia have fallen 4.7% on a rolling three-month basis to the end of April compared to the prior year, with this trend persisting into May and June.
Market Share Gains Offset Volume Decline
Despite the overall market contraction, Monash IVF has managed to increase its national market share by 1.0 percentage point to 20.1% over the same period. Some states have recorded significant market share improvements, suggesting Monash IVF’s competitive positioning is strengthening even as the broader market softens. This dynamic highlights the company’s ability to capture a larger slice of a shrinking pie.
International Growth and Clinical Network Expansion
On the international front, Monash IVF’s operations are performing well, with second half FY26 volumes expected to be materially higher than the prior corresponding period. The company has also bolstered its clinical network, notably adding key fertility specialists in Victoria and New South Wales. These moves follow the appointment of inaugural Chief Medical Officer Fleur Cattrall, signalling a focus on clinical strength and service quality.
Cost Initiatives to Support Future Profitability
Operational and cost efficiency programs announced at the half-year mark are underway, but their impact on FY26 earnings is limited due to timing. Monash IVF expects these initiatives to contribute more substantially in FY27, potentially offsetting some of the current market headwinds. CEO Victoria Atkinson emphasised that while the company has taken steps to reduce costs and improve operational performance, the benefits will be more meaningful in the next financial year.
Looking Ahead to Full Year Results
Monash IVF plans to provide a comprehensive update with its FY26 full year results announcement scheduled for 24 August 2026. Investors will be watching closely to see if the company’s operational improvements and international growth can counterbalance the domestic market softness and deliver on profit expectations.
Bottom Line?
Monash IVF’s profit downgrade underscores persistent softness in the Australian IVF market, but its market share gains and international growth set the stage for a potentially stronger FY27.
Questions in the middle?
- Will Monash IVF’s operational efficiencies deliver the expected earnings uplift in FY27?
- How sustainable are the company’s recent market share gains amid ongoing domestic volume declines?
- To what extent can international growth offset Australian market headwinds going forward?
